SIGA provides an update on its monkeypox program, while Massive Bio announces progress on its AI platform for connecting cancer patients to trials, with additional updates from BridgeBio, the Oncology Institute, and CROs Caidya, Charles River Labs, Syneos Health and PPD parent Thermo Fisher Scientific.

Public Company Edition: Prime Medicine raised $175m, making its offering the sixth-largest out of 19 biopharma IPOs in the US this year. Also, Oculis and AUM opted to go public via SPAC mergers, Insmed raised $775m from multiple financings and Dice capitalized on positive data with a $300m offering.

The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.

SIGA chief scientific officer Dennis Hruby spoke with Scrip about how the company is developing its drug, Tpoxx, to address the monkeypox outbreak.